Abiopharma

🔍 Eizen Joshua M (Executive)

Company: AN2 Therapeutics, Inc. (ANTX)

Report Date: 2026-01-05

Detailed Transactions and Holdings:

• Sold 17,923 shares of Common Stock at $1.0014 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: false | shares_owned_after: 159,430.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 6,931 shares of Common Stock at $1.012 per share (Direct)
  Date: 2026-01-06 | Code: S | equity_swap_involved: false | shares_owned_after: 152,499.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026.
• F2: This transaction was executed in multiple trades at prices ranging from $1.001 to $1.003 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F3: Includes (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 60,000 RSUs which vest as follows: 25% of the RSUs vest on January 1, 2025, 50% of the RSUs vest on January 1, 2026, and 25% of the RSUs vest on July 1, 2026, (c) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, and (d) 58,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service as of such date.
• REMARKS: Chief Operating Officer and Chief Legal Officer